Clinical Trials
17 trialsNCT03866382 2026-05-26
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03291028 2026-05-22
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
Fox Chase Cancer Center
Active not recruiting
NCT02496208 2026-05-13
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03237780 2026-05-13
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04963153 2026-05-13
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05092958 2026-05-13
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02012699 2026-05-05
iCaRe2
University of Nebraska
Recruiting
NCT07124000 2026-05-01
DP-04
AstraZeneca
Recruiting
NCT00479128 2026-04-16
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04953104 2026-04-15
ARID1A and/or KDM6A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT01352962 2026-04-14
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03288545 2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2 Terminated
NCT05888532 2026-03-17
64Cu-GRIP B in Patients With Advanced Malignancies
University of California, San Francisco
Phase 1/2 Recruiting
NCT04004442 2026-03-13
COAXIN
University of Oklahoma
Phase 1 Active not recruiting
NCT04940299 2026-03-06
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02812420 2026-03-05
Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting